Innate Pharma (IPHYF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 27,899 | 10,130 | 22,110 | 18,360 | 16,350 |
| Cost of Goods | N/A | 21,430 | 14,170 | 12,750 | 15,160 |
| Gross Profit | 27,899 | -11,300 | 7,940 | 5,610 | 1,180 |
| Operating Expenses | 39,854 | 15,240 | 11,390 | 10,380 | 11,550 |
| Operating Income | -11,954 | -26,110 | -3,280 | -4,020 | -10,200 |
| Interest Expense | 2,913 | 540 | 0 | 0 | 0 |
| Other Income | 7,425 | 540 | -560 | -90 | 480 |
| Pre-tax Income | -7,442 | -26,110 | -3,840 | -4,110 | -9,720 |
| Net Income Continuous | -7,442 | -26,117 | -3,841 | -4,114 | -9,722 |
| Net Income | $-7,442 | $-26,110 | $-3,840 | $-4,110 | $-9,720 |
| EPS Basic Total Ops | -0.14 | -0.52 | -0.10 | -0.11 | -0.26 |
| EPS Basic Continuous Ops | -0.14 | -0.52 | -0.10 | -0.11 | -0.26 |
| EPS Diluted Total Ops | -0.14 | -0.52 | -0.10 | -0.11 | -0.26 |
| EPS Diluted Continuous Ops | -0.14 | -0.52 | -0.10 | -0.11 | -0.26 |
| EBITDA(a) | $-9,009 | $-23,000 | $-2,120 | $-2,950 | $-8,950 |